Pharmaceutical - Diabetes, Pricing

Filter

Current filters:

DiabetesPricing

Popular Filters

1 to 25 of 38 results

Call for Indian govt to bring more essential drugs under price control from NGOs

Call for Indian govt to bring more essential drugs under price control from NGOs

22-08-2014

Non-governmental organizations in India have jointly issued a letter calling on the country’s government…

Cardio-vascularDiabetesIndiaNational Pharmaceuticals Pricing AuthorityPharmaceuticalPoliticsPricing

Added benefit of Novo Nordisk’s Tresiba not proven, says IQWiG

Added benefit of Novo Nordisk’s Tresiba not proven, says IQWiG

08-08-2014

In an early benefit assessment under the German Act on the Reform of the Market for Medicinal Products…

DiabetesGerman Institute for Quality and EfficiencyGermanyNovo NordiskPharmaceuticalPricingRegulationTresiba

Added benefit of Invokana in type 2 diabetes is not proven, says IQWiG

Added benefit of Invokana in type 2 diabetes is not proven, says IQWiG

17-06-2014

In an early benefit assessment under the German Act on the Reform of the Market for Medicinal Products…

DiabetesGermanyInvokanaJanssen-CilagJohnson & JohnsonPharmaceuticalPricingRegulation

Large increase seen in insulin use, out-of-pocket costs for type 2 diabetes

11-06-2014

Largely attributable to the widespread adoption of insulin analogs, use of insulin among patients with…

DiabetesHealthcarePharmaceuticalPricingUSA

Negative IQWiG view on AstraZeneca’s combo diabetes drug Xigduo

16-05-2014

In an early benefit assessment under the German Act on the Reform of the Market for Medicinal Products…

AstraZenecaDiabetesGermanyPharmaceuticalPricingRegulationXigduo

UK’s NICE backs Janssen’s Invokana for type 2 diabetes

16-05-2014

Janssen, a subsidiary of US health care giant Johnson & Johnson, said today that it welcomes the publication…

DiabetesInvokanaJanssenJohnson & JohnsonPharmaceuticalPricingRegulationUK

Ukraine MoH signs “understanding” with insulin producers

24-03-2014

On March 19, Oleg Musiy, the Minister of Health in Ukraine, signed the memorandum of understanding with…

DiabetesEastern EuropeHealthcarePharmaceuticalPricingUkraine

Latest Australian PBS Listings include medicines for children

Latest Australian PBS Listings include medicines for children

19-03-2014

Ten new medicines to treat a range of illnesses from rare forms of cancer to skin conditions will be…

Anti-Arthritics/RheumaticsAsia-PacificAustraliaDermatologicalsDiabetesGastro-intestinalsHealthcareOncologyPharmaceuticalPricing

Ukraine adopts Resolution

Ukraine adopts Resolution "on postponement of the Insulin Pilot Project"

10-03-2014

Last week, the Ukraine Cabinet of Ministers (CMU) put off the beginning of price declaration on insulin…

DiabetesEastern EuropePharmaceuticalPricingUkraine

NICE consults on draft guidance backing Invokana, as drug debuts in the UK

24-02-2014

UK drugs watchdog the National Institute for Health and Care Excellence is currently appraising Invokana…

DiabetesInvokanaJanssen-CilagJohnson & JohnsonMarkets & MarketingNorthern EuropePharmaceuticalPricingRegulationUK

Pharma appeals to Ukraine Health Ministry on insulin supply problems

Pharma appeals to Ukraine Health Ministry on insulin supply problems

27-01-2014

The Association of Pharmaceutical Research and Development and the American Chamber of Commerce in Ukraine…

DiabetesEastern EuropeHealthcarePharmaceuticalPricingUkraine

Lack of pricing accord sees Bristol-Myers and AstraZeneca pull Forxiga in Germany

Lack of pricing accord sees Bristol-Myers and AstraZeneca pull Forxiga in Germany

14-12-2013

Drug majors Bristol-Myers Squibb and AstraZeneca have reportedly decided to stop marketing their diabetes…

AstraZenecaBristol-Myers SquibbDiabetesEuropeForxigaMarkets & MarketingPharmaceuticalPricing

Germany’s IQWiG sees no added benefit of Onglyza as monotherapy

Germany’s IQWiG sees no added benefit of Onglyza as monotherapy

05-12-2013

In an early benefit assessment under the Act on the Reform of the Market for Medicinal Products (AMNOG),…

AstraZenecaBristol-Myers SquibbDiabetesEuropeOnglyzaPharmaceuticalPricingRegulation

UK’s NICE says yes to Alimera’s Iluvien

27-11-2013

In final guidance published this morning by UK drugs watch dog the National Institute for Health and…

Alimera SciencesDiabetesEuropeIluvienOphthalmicsPharmaceuticalPricingRegulation

Pilot project in Ukraine for regulation of insulin preparation pricing

16-09-2013

Last week in the Ukraine, the Association of Pharmaceutical Research and Development (APRaD) and the…

DiabetesEuropePharmaceuticalPricing

First IQWiG assessment of the established drug market finds advantage for Januvia

15-07-2013

There are hints of a minor added benefit of US drug giant Merck & Co's (NYSE: MRK) Januvia (sitagliptin)…

DiabetesEuropeMerck & CoPharmaceuticalPricingRegulation

High out-of-pocket costs for DPP-IV inhibitors and GLP-1 analogues greatly limit prescribing in Brazil, Mexico and Argentina

03-07-2013

Premium-priced DPP-IV inhibitors and GLP-1 analogues used in the treatment of type 2 diabetes lack nationwide…

DiabetesMarkets & MarketingPharmaceuticalPricingSouth America

UK's NICE backs NHS use of Bristol-Myers/AstraZeneca's Forxiga

30-05-2013

UK drugs watchdog the National Institute for Health and Care Excellence (NICE) today (May 30) issued…

AstraZenecaBristol-Myers SquibbDiabetesEuropeForxigaPharmaceuticalPricingRegulation

Germany's IQWiG finds no added benefit for AstraZeneca and Bristol-Myers' Forxiga

25-03-2013

In an early benefit assessment under the German Act on the Reform of the Market for Medicinal Products…

Bristol-Myers SquibbDiabetesEuropeForxigaPharmaceuticalPricingRegulation

Novo Nordisk now ready to launch Tresiba in Japan, following pricing accord

13-02-2013

Danish insulin giant Novo Nordisk (NOV: N) yesterday announced that it has received approval of the price…

Asia-PacificDegludecDiabetesMarkets & MarketingNovo NordiskPharmaceuticalPricingTresiba

Negative NICE guidance for Roche's Avastin and B-MS/AstraZeneca's Forxiga

01-02-2013

UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) has published draft…

AstraZenecaAvastinBristol-Myers SquibbDiabetesEuropeForxigaOncologyPharmaceuticalPricingRegulationRoche

1 to 25 of 38 results

Back to top